Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 886 / https://doi.org/10.3332/ecancer.2018.886

Research

ReDO_DB: the repurposing drugs in oncology database

Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project.org/db/).

Keywords: Drug repurposing, repositioning, ReDO project, cancer drugs, online database

Loading Article Metrics ... Please wait

Related articles

Review: Fertility preservation in ovarian tumours

Abstract | Full Article | PDF Published: 06 Dec 2018 / https://doi.org/10.3332/ecancer.2018.885

Research: Detection of precancerous lesions in the cervix and HPV infection in women in the region of Maniapure, Bolivar State

Abstract | Full Article | PDF | Spanish Published: 03 Dec 2018 / https://doi.org/10.3332/ecancer.2018.884

Review: Targeted literature review of the global burden of gastric cancer

Abstract | Full Article | PDF Published: 26 Nov 2018 / https://doi.org/10.3332/ecancer.2018.883

Case Report: Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation

Abstract | Full Article | PDF | Spanish Published: 20 Nov 2018 / https://doi.org/10.3332/ecancer.2018.882

Short Communication: Learning from the past to design better trials in second-line treatment for mesothelioma patients

Abstract | Full Article | PDF Published: 08 Nov 2018 / https://doi.org/10.3332/ecancer.2018.881



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation